市场调查报告书
商品编码
1447735
疫苗市场评估:按类型、给药途径、适应症、年龄层、最终用户和地区划分的机会和预测(2017-2031)Vaccine Market Assessment, By Type, By Route of Administration, By Disease Indication, By Age Group, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
全球疫苗市场规模将从2023年的1413亿美元增长到2031年的1796.9亿美元,2024年至2031年的预测期内复合年增长率为3.05%。据预测。
全球疫苗市场的推动因素包括癌症疫苗研究资金的增加、政府对疫苗接种活动的支持举措、DTaP 疫苗需求的增加、结合疫苗的使用增加以及患者支持和教育举措的增加。它由以下因素组成。
增加癌症疫苗研究的经费
全球疫苗市场的扩张高度依赖癌症疫苗研究资金的增加。 鼓励创新和加速癌症疫苗开发的政府计画包括赠款、补贴和税收优惠。 这笔资金使科学家能够进行重要的临床试验,进行深入研究,并探索专门用于对抗癌症的新疫苗接种技术。 这笔资金支持将确保疫苗符合严格的安全要求并赢得市场信心,为疫苗成功商业化打开大门。
政府为疫苗接种活动所做的努力
世界各国政府透过其疫苗接种政策和计划为全球疫苗市场做出了重大贡献。 疫苗接种活动是向大量人群和儿童快速接种疫苗的一种手段。 它可以针对单一抗原或针对国家或国家以下各级的组合实施,这取决于国家的需求和目标。 透过赞助此类活动,您可以确保公平、平等地获得疫苗,同时提高大众对疫苗重要性和可靠性的认识。 这项策略增加了疫苗接种率,提高了免疫率,并改善了社区健康。 此外,政府经常资助旨在消除对疫苗的误解和普遍恐惧并建立社区信心的教育活动。
对 DTaP 疫苗的需求不断增加
由于对 DTaP(白喉、破伤风、百日咳)疫苗接种的需求不断增加,全球疫苗市场也不断扩大。 需求增加的主要原因是需要解决百日咳、破伤风和白喉等疾病发生率上升的问题。 高出生率和百日咳疫苗接种接受度的提高是 DTaP 疫苗市场的主要驱动因素。 含有 DTaP 成分的组合疫苗的推出也有助于市场成长。 为了满足这种不断增长的需求,各国政府和製药公司正在投资研发,刺激全球疫苗市场的创新和成长。
本报告调查了全球疫苗市场,提供了市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、行业结构以及影响市场成长的因素分析。我们编制了案例研究、竞争格局、主要公司的简介等等。
The global vaccine market is projected to witness a CAGR of 3.05% during the forecast period 2024-2031F, growing from USD 141.3 billion in 2023 to USD 179.69 billion in 2031F. The global vaccine market is shaped by increasing funding for cancer vaccine research, supportive government initiatives for vaccination campaigns, increased demand for DTaP vaccines, growing use of conjugate vaccines, and an increase in initiatives to support and educate patients.
The development of vaccinations against different types of malignancies has been made possible by increased funding in research, which has had a significant impact on the global vaccine market. The possibility of using immunological therapies to prevent or treat cancers increases with advances in scientific understanding. A surge in the demand for vaccinations against diphtheria, tetanus, and pertussis in the global vaccine market suggests that parents are becoming more conscious of diseases that can be prevented and are eager to shield their kids from potentially fatal conditions like whooping cough.
The initiatives taken by the governments are one of the major reasons for the substantial growth of the global vaccine market. Governments worldwide are actively promoting vaccination programs as part of their public health strategies. By supporting these efforts with resources and policy changes, governments aim to improve accessibility and coverage rates for essential vaccinations. The capacity of conjugate vaccines to offer enduring defense against bacterial infections, such as Streptococcus pneumoniae, Neisseria meningitidis serogroup C, and Haemophilus influenzae type b (Hib), has led to their increased popularity in the global vaccine market. Moreover, their rapid adoption around the world is largely due to their efficacy and safety profile.
Building trust between healthcare practitioners and patients is greatly aided by initiatives to educate and empower patients about the advantages and hazards of vaccinations. These kinds of programs also assist in clearing up misconceptions about vaccinations, which improves general adherence to advised schedules, leading to growth in the global vaccine market.
Pfizer India and Apollo Hospital jointly opened a Centre of Excellence (CoE) for adult immunization in Hyderabad in May 2023. Apollo Hospital aimed to safeguard patients from vaccine-preventable diseases (VPDs) and increase adult vaccination adoption through the establishment of an end-to-end ecosystem within the hospital.
Increased Funding for Cancer Vaccine Research
The expansion of the global vaccine market is largely dependent on increased financing for cancer vaccine research. Government programs that promote innovation and hasten the development of cancer vaccines include grants, subsidies, and tax breaks. This funding allows scientists to undertake critical clinical trials, carry out in-depth investigations, and investigate novel vaccination technologies that are specifically designed to fight cancer. This financing opens the door for the successful commercialization of vaccines by guaranteeing that they meet strict safety requirements and acquire the confidence of the market. This eventually improves public health outcomes and advances medical research in the battle against cancer.
For example, in June 2023, Pancreatic Cancer North America (PCNA) and Stand Up to Cancer (SU2C) announced PCNA's contribution of USD 1.5 million to SU2C to support pancreatic cancer vaccine development. The trial's vaccination was specifically designed to identify the cancer cells found in each participant's pancreatic cancer tumor and boost the immune system's ability to combat the malignancy.
Government Initiatives for Vaccination Campaigns
Governments across the globe are driving substantial contributions to the global vaccine market using vaccination policies and programs. Vaccination campaigns are a means of promptly administering vaccines to a large group of people or children. Depending on the needs and goals of the nation, they can be carried out at the national or sub-national level, for a single antigen, or in combination. Through their sponsorship of these activities, they ensure fair and equal access to vaccines, while increasing public knowledge of their importance and dependability. This strategy encourages greater vaccination acceptance, which raises immunization rates and improves community health outcomes. Furthermore, governments frequently provide funding for educational initiatives aimed at dispelling myths and common worries about vaccines, fostering community trust.
The Human Papillomavirus (HPV) vaccination campaign was initiated by the Government of Bangladesh in October 2023, with assistance from UNICEF, the Vaccine Alliance (Gavi), and the World Health Organisation (WHO). By preventing cervical cancer, a disease that kills thousands of women in Bangladesh each year, this program seeks to safeguard the health and future of millions of girls throughout the nation.
Increased Demand for DTaP Vaccines
The global vaccine market is expanding due to the rising demand for DTaP (Diphtheria, Tetanus, and Acellular Pertussis) vaccinations. The primary reason for this growth in demand is the need to address the rising incidence of diseases, including pertussis, tetanus, and diphtheria. The high birth rate and the growing acceptance of the pertussis vaccination are the main drivers of the DTaP vaccine market. The launch of combination vaccines with DTaP components also contribute to the growth of the market. To fulfill this growing need, governments and pharmaceutical companies are making investments in R&D, which is spurring innovation and growth in the global vaccine market.
In December 2023, India, Panacea Biotec, the biotechnology company, introduced EasyFourPol, a fully liquid pentavalent vaccination based on wP-IPV. Children are protected against five lethal diseases by the wP-IPV pentavalent vaccine: invasive infections caused by Haemophilus influenza type B, pertussis, polio, tetanus, and diphtheria. Furthermore, the company declared that Panacea Biotec Germany GmbH, its step-down, wholly owned subsidiary, had registered Valganciclovir 50 mg/mL powder for oral solution in Germany.
Growing Use of Conjugate Vaccines
The global vaccination market is expanding due to the increasing usage of conjugate vaccines. The use of conjugate vaccines has increased because of their success in lowering the incidence of diseases and promoting strong immunity, particularly in susceptible groups such as young children and newborns. Due to their proven ability to effectively target a variety of diseases, these vaccines are essential components of global immunization programs. Researchers have been able to build conjugate vaccines with increased features, broadening their usefulness across numerous diseases, primarily made possible through advancements in biotechnology and vaccine development.
The World Health Organization (WHO), in February 2024, granted prequalification (PQ) approval to SK Bioscience, a South Korean biotech and vaccine business dedicated to advancing human health from prevention to cure, for their typhoid conjugate vaccine (TCV), SKYTyphoid. The company has already gotten two influenza vaccinations and a varicella vaccine. This is its fourth WHO PQ.
North America Dominating the Market
The global vaccine market is dominated by North America. This dominance is primarily due to the region's robust immunization and health welfare programs, solid government policies, and sophisticated research skills. North America's position as a major player in the global vaccination industry is further cemented by the existence of respectable manufacturers and sufficient financing regulations. Furthermore, the region's emphasis on raising the coverage of immunizations through partnerships and government initiatives supports its continued growth and market leadership. Increased knowledge and understanding of vaccines in these nations motivate people to seek prompt medical care, which fuels demand for vaccine treatments and aids in the growth of the global vaccine market
Valneva SE, a specialty vaccine manufacturer, declared in November 2023 that IXCHIQ, a single-dose, live-attenuated vaccine developed by Valneva, has been approved by the FDA for the prevention of chikungunya virus (CHIKV)-related illness in people 18 years of age and older who are at an increased risk of exposure.
Future Market Scenario (2024 - 2031F)
By utilizing the skills and extensive knowledge of innovation leaders, major firms in the global vaccination market are cooperating to share next-generation vaccine platforms, helping them get past hurdles to competition.
To find new development opportunities, companies in the worldwide vaccine market are working on needle-free delivery and investigating emerging disease indications like CMV and glioblastoma, an aggressive form of cancer.
Nucleic acid-based vaccines have shown considerable promise in treating HIV and cancer. As a result, the global vaccine market is expected to rise at a promising rate.
Asthma, diabetes, and respiratory syncytial virus (RSV) infections are among the new disease categories that companies in the global vaccine market are investigating, and which have not yet been the subject of vaccine research.
Key Players Landscape and Outlook
To maximize benefits and increase their market share, major players in the global vaccine market are collaborating more and more. Through these partnerships, businesses may pool their knowledge, assets, and technological know-how to expedite vaccine research, expand manufacturing capabilities, and effectively tackle global health concerns. Companies can efficiently bring breakthrough vaccines to market by collaborating with other businesses to obtain complementary talents, share knowledge, and pool resources. This cooperative strategy ensures a more thorough response to public health demands, promotes research improvements, and improves the vaccination market, in addition to encouraging innovation.
A strategic alliance was announced on February 26, 2024, by Takeda and Biological E. Limited (BE), a well-known pharmaceutical and vaccine company in India, to expedite access to QDENGA (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) multi-dose vials (MDVs). To boost national immunization programs, governments in endemic countries will eventually be able to purchase these doses by 2030 at the latest.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.